Live feed16:05:00·21dPRReleasevia QuantisnowSpyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026ByQuantisnow·Wall Street's wire, on your screen.SYRE· Spyre Therapeutics Inc.Health Care
